NuVasive Inc

NuVasive — Q2 2016 Earnings Presentation

15 slides from NuVasive's earnings presentation, Jul 26, 2016

  1. Slide 1: Second Quarter 2016 Results

    Exhibit 99.2 NuVasive, Inc. Second Quarter 2016 Results Supplemental Presentation to Earnings Press Release July 26, 2016

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements NuVasivecautionsyou that statementsincludedin this presentationthat are not a descriptionof historical factsare forward-lookingstatementsthat involverisks,uncertainties,assumptionsand other factorswhich, if they do not materializeor provecorrect,couldcauseNuVasive’sresults

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures Managementusescertain non-GAAPfinancial measuressuchas non-GAAPearningsper share,non-GAAP net income, non-GAAPoperating expenses and non-GAAPoperating profit margin, which exclude amortization of intangible assets, purchase accounting related charges, leasehold related ch

  4. Slide 4: Second Quarter 2016 Performance Highlights

    Second Quarter 2016 Performance Highlights* Double-digit revenue growth and increase in full year 2016 guidance Reported double-digit revenue growth of 16.4% to $236.2M, or 16.1% constantcurrency;excludingNuVasiveSpecializedOrthopedics,Inc(NSO), core revenue grew 9.0%, or 8.6% constant currency Deli

  5. Slide 5: NuVasive's Formula for Success

    NuVasive’sFormula for Success Fueling 2016 strategic agenda with proven approach to win Industry disruptor Driving organic growth adding value and with numerous inorganic addressing unmet needs opportunities available Operational excellence delivering significant margin expansion 5 ©2016 NuVasive®,

  6. Slide 6: Second Quarter 2016 Revenue Highlights

    Second Quarter 2016 Revenue Highlights Strong revenue performance in key growth areas U.S. SPINAL HARDWARE U.S. SURGICAL SUPPORTINTERNATIONAL Includes All Implants, Fixation, MAGEC® Includes Biologics, IOM Services Includes Puerto Rico & PRECICE® & Disposables Up 18.3% in 2Q16 Up 3.5% in 2Q16 Up 33.

  7. Slide 7: Second Quarter 2016 P&L Performance

    Second Quarter 2016 P&L Performance Operating leverage story continues to play out 2Q16 2Q16 YoY Actuals Performance Factors Non-GAAP Measures 170bps drivenby med device tax repeal & Gross Margin 77.8% favorable contribution from NSO 40 bps driven by addition of NSO Sales, Marketing & Admin. 56.9% R

  8. Slide 8: Driving Improved Financial Profile

    Driving Improved Financial Profile Improving Adjusted EBITDA profile Incremental focus on improving the Disciplined approach to driving profitability working capital profile and CapEx resulting in meaningful improvements in spending will drive incremental Adjusted EBITDA profile gains in the free ca

  9. Slide 9: Driving Improved Financial Profile

    Driving Improved Financial Profile Improving Non-GAAP Operating Profit Margin Increased focus on driving improved Non-GAAP Operating profitability through disciplined Profit Margin spending and improved efficiencies in 20% core business while adding acquired ~16% businesses that complement the 15.8%

  10. Slide 10: Driving Improved Tax Rate

    Driving Improved Tax Rate Increased focus on driving improved tax rate through international scale and domestic tax planning Long Term Tax Rate Goals Opportunity to drive non-GAAP 43% 42% effective tax rate lower by 41% ~1,400 bps over 5 years 39% 37% 37% Operational Improvements 35% 34% Taking Hold

  11. Slide 11: Strategic Milestone: Completed Biotronic NeuroNetwork Acquisition

    Strategic Milestone: Completed Biotronic NeuroNetworkAcquisition AcceleratesNuVasive’stransitionfroma spineimplantcompanyto a spinesolutions companyofferinga broadrangeof integratedcapabilities to deliverrobustimproved clinical and economic outcomes for patients and hospitals. • DeliversClinicalFulf

  12. Slide 12: Strategic Milestone: Medtronic Settlement

    Strategic Milestone: Medtronic Settlement General • Reached a definitive agreement with Medtronic to settle over 8 years of ongoing patent litigation between the two companies • Removes associated expense of the legal proceedings and provides a clear protocol for resolution of potential patent dispu

  13. Slide 13: ASU 2016-09 Share-Based Compensation

    ASU 2016-09 Share-Based – Compensation Background:New FASBguidanceissuedin March 2016that requiresmandatoryadoption in 2017, with early adoption permitted. The Company chose to adopt in the second quarter of 2016, which requires adoption effective as of January 1, 2016. The adoption resulted in a re

  14. Slide 14: Full Year 2016 Financial Performance Guidance

    Full Year 2016 Financial Performance Guidance* Reflects impact of acquisitions, convertible note issuance, note repurchases, expected currency rates & adoption of the ASU FY16 Guidance Performance Drivers Revenues • As reported ~$962.0M, ~18.5% YoYgrowth^ ~$53M NSO contribution, ~$27M Biotronic; ~$1

  15. Slide 15: Why Invest in NuVasive

    Why Invest in NuVasive Relentless focus on driving shareholder value Competitively positioned in large and growing global spine market with favorable transformative dynamics playing to NuVasive strengths Industry-leading innovation and Drive surgeon conversion, Double International revenue integrate

Nuvasive — Q2 2016 Earnings Presentation on 6ix